### Indication
- Palliative care

### INN
- Ondansetron

### Medicine type
- Chemical agent

### List type
- Core (EML)
- Core (EMLc)

### Formulations
- **Parenteral > General injections > IV:** 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
- **Oral > Liquid:** 4 mg per 5 mL (ondansetron base)
- **Oral > Solid:** 4 mg (ondansetron base) ; 8 mg (ondansetron base)

### EML status history
- First added in 2011 (TRS 965)
- Changed in 2019 (TRS 1021)
- Changed in 2021 (TRS 1035)

### Sex
- All

### Age
- Also recommended for children

### Age restriction
- > 1 month

### Therapeutic alternatives
- dolasetron (ATC codes: A04AA04)
- granisetron (ATC codes: A04AA02)
- palonosetron (ATC codes: A04AA05)
- tropisetron (ATC codes: A04AA03)

### Patent information
- Patents have expired in most jurisdictions
- Read more about patents.

### Summary of evidence and Expert Committee recommendations
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that dolasetron, granisetron, palonosetron and tropisetron be specified as therapeutic alternatives under the square box listing for ondansetron on the EML and EMLc.